ArriVent BioPharma Enters China License for ARR-002; Reports Q2 Results

What Happened ArriVent BioPharma, Inc. announced on August 11, 2026 that it entered a Collaboration and License Agreement with Shanghai Allist Pharmaceuticals Co., Ltd. granting Allist an exclusive, sublicensable license to research, develop, manufacture and commercialize ARR-002 in Greater China (PRC, Hong Kong, Macau and Taiwan). The company retains all rights to ARR-002 outside the Licensed Territory, will supply ARR-002 for the start of the initial joint global clinical study, and the collaboration establishes a joint committee to coordinate global development. On August 12, 2026 ArriVent also issued a press release reporting its financial results for the quarter ended June 30, 2026 (Exhibit 99.1 to the filing).

Key Details

• Agreement date: August 11, 2026; press release on results dated August 12, 2026 for Q2 ended June 30, 2026.
• Potential payments to ArriVent up to $80.6 million (upfront + development, regulatory and sales milestones).
• Tiered royalties payable to ArriVent in the mid-single digit to low double-digit percentages on annual net sales in the Licensed Territory; royalties run product-by-product and country-by-country for the later of certain patent expirations, regulatory exclusivity expiration, or a specified number of years after first commercial sale.
• Allist is responsible for development and commercialization in Greater China; ArriVent retains manufacturing rights in the Licensed Territory for ARR-002 and all rights outside the Licensed Territory.

Why It Matters This deal provides ArriVent a non-dilutive path to fund and advance ARR-002 in a large market (Greater China) through a local partner while preserving global upside (the company keeps rights outside China). The upfront, milestone and royalty structure (up to $80.6M plus ongoing royalties) could meaningfully affect future revenue if development and sales milestones are achieved. Investors should review the August 12, 2026 press release (Exhibit 99.1) for the company’s reported Q2 2026 financial results and monitor progress of the ARR-002 collaboration for milestone triggers and potential revenue impacts.